Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue used clinically to assess growth hormone secretion. It is of interest to researchers for its ability to improve bone density, reduce scaring, fight the effects of dementia, and reduce seizure activity.
Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue used clinically to assess growth hormone secretion. It is of interest to researchers for its ability to improve bone density, reduce scaring, fight the effects of dementia, and reduce seizure activity.
Sermorelin is a growth hormone releasing hormone derivative and, as such, produces all of the same effects that GH produces, including increasing muscle mass, boosting long bone growth, and reducing adipose tissue. Even though the effects are the same, the side effects are not. In fact, sermorelin is the preferred way to increase GH levels in humans, even over the exogenous administration of growth hormone itself. The primary reason for this preference is that sermorelin is subject to physiological feedback mechanisms that help to prevent common problems encountered with GH administration. These problems include overdose, improper dosing, and unintended side effects like edema, joint pain, and dysregulation of normal physiology.